MDT
Medtronic (MDT)
NYSE
$101.89-$0.43 (-0.42%)
Price as of Nov 18, 2026 7:40 AM EST
  • $130.9B
    Market Cap
  • 4.87%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: 52
  • Momentum Score: 40
  • True Yield: 29
  • Financial Health Score: 66
TradeSmith Loading

Latest Research & News

Nerve Repair and Regeneration - Global Market Share Analysis, Industry Trends, Growth Forecasts, 2026-2031 | AI-Enabled Devices and Biomaterials Fuel 11.96% CAGR

The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.

11/17/2026, 11:00 AM • GlobeNewswire

5 Dividend Stocks to Buy and Hold Forever

The article recommends five dividend stocks suitable for long-term buy-and-hold investors: Johnson & Johnson, Medtronic, Procter & Gamble, Federal Realty Investment Trust, and Realty Income. All five companies have strong dividend track records with at least 32 years of consecutive annual increases, combined with well-run underlying businesses that generate reliable income streams.

11/14/2026, 4:15 PM • The Motley Fool

Transcatheter Aortic Valve Replacement Market to Reach US$ 30.01 Billion by 2035 at 15.2% CAGR, Driven by Improved Clinical Outcomes and Increasing Adoption of Catheter-Based Cardiac Interventions | Exclusive Report by The Insight Partners

The global Transcatheter Aortic Valve Replacement (TAVR) market is projected to grow from US$ 8.41 billion in 2025 to US$ 30.01 billion by 2035, driven by increasing prevalence of aortic stenosis, aging populations, and rising adoption of minimally invasive cardiac procedures. Technological advancements in valve platforms and delivery systems are creating growth opportunities, with Asia Pacific emerging as the fastest-growing region.

11/12/2026, 4:54 AM • GlobeNewswire

Intuitive Surgical Placed 546 da Vinci Systems Last Quarter. Why Wall Street's Sell-Off Misses the Point.

Intuitive Surgical's stock fell despite strong quarterly results, but investors are overlooking the company's true business model. While da Vinci robot sales account for only 25% of revenue, the remaining 75% comes from services, instruments, and accessories for its installed base of 12,094 systems. With procedure volumes up 15% year-over-year and the surgical robotics market still in early adoption stages, the company's recurring revenue stream remains robust despite competitive pressures from Medtronic and Johnson & Johnson.

11/08/2026, 2:15 PM • The Motley Fool

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

The article compares two healthcare disruptors: Hims & Hers Health, a high-growth telehealth platform with 59% revenue growth but facing regulatory scrutiny, and Intuitive Surgical, a dominant medical robotics leader with strong profitability and a 12% increase in installed systems. While both stocks declined in 2026, the author recommends Intuitive Surgical for its stronger competitive moat and market position, despite both being considered speculative investments.

11/06/2026, 10:05 PM • The Motley Fool

Global Sacral Neuromodulation Market Size, Share, Trends and Forecast 2026-2036: Rechargeable, MRI-Compatible Systems Drive 11.1% CAGR

The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.

11/06/2026, 10:58 AM • GlobeNewswire

Orchestra BioMed Announces Pricing of Public Offering

Orchestra BioMed (OBIO) announced the pricing of an underwritten public offering of 15 million shares at $5.00 per share, expected to raise $75 million in gross proceeds. The company plans to use the funds to advance its AVIM Therapy program and BACKBEAT clinical trial for hypertension treatment, as well as its Virtue SAB program for coronary in-stent restenosis, alongside other research and development initiatives.

11/05/2026, 10:42 PM • GlobeNewswire

Continuous Glucose Monitoring Market in India: USD 452.9 Million Opportunity by 2032 as Digital Diabetes Care Expands, Reports Mordor Intelligence

India's continuous glucose monitoring market is projected to grow at a CAGR of 11.90% from 2027-2032, reaching USD 452.9 million by 2032. The market expansion is driven by growing adoption of sensor-based monitoring, digital healthcare integration, and expanding diabetes management programs. However, high device costs and limited reimbursement coverage remain barriers to wider adoption.

11/03/2026, 2:30 AM • GlobeNewswire

The Best Dividend Stocks to Buy With $5,000 in November

The article recommends three dividend stocks as attractive buying opportunities in November: AbbVie, Johnson & Johnson, and Medtronic. Despite pressure from higher-growth AI stocks and rising Treasury yields, these Dividend Kings offer solid long-term value with strong cash flow generation and room for future dividend increases. AbbVie benefits from successful drug launches offsetting Humira losses, J&J's streamlined business shows steady growth, and Medtronic's turnaround from past challenges presents a bargain valuation.

11/02/2026, 12:15 PM • The Motley Fool

Medtronic Just Retired 55 Million Shares Without Spending Cash. Is the Stock a Buy?

Medtronic completed a spinoff of its diabetes segment (MiniMed) and retired 55 million shares without cash expenditure, which will boost future EPS. The company reported strong Q1 FY2027 results with 14% revenue growth and is approaching Dividend King status (49 consecutive years of increases). Despite operational improvements and a reinvigorated pipeline with 50+ FDA approvals, Medtronic trades at a discount to medtech peers.

11/01/2026, 12:21 AM • The Motley Fool

Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact

Boston Scientific (BSX) stock fell 6% after the medical device maker cut its Q4 sales and full-year EPS guidance due to ongoing disruptions from an August cyberattack. The company estimated the eight-day cyberattack cost it 300 basis points in sales growth and $0.07 in adjusted EPS. Management expects a slow recovery with 2027 projected as the trough year, though the stock now trades at a relatively low 13x forward earnings multiple.

10/28/2026, 4:50 PM • The Motley Fool

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale

The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.

10/21/2026, 5:00 AM • GlobeNewswire

How Many Shares Would It Take to Earn $1,000 a Year From This Future Dividend King?

Medtronic is one year away from achieving Dividend King status with 49 consecutive years of dividend increases. An investor would need approximately 348 shares (costing ~$32,792) to generate $1,000 in annual dividend income at the current 3% yield. The recent MiniMed spinoff positions Medtronic to focus on higher-margin businesses, potentially enabling larger dividend increases and earnings growth of 7-8% in coming years.

10/17/2026, 8:06 AM • The Motley Fool

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories and Intuitive Surgical represent different healthcare investment strategies. Abbott offers diversified operations across diagnostics, nutrition, and medical devices with a conservative 18x forward P/E ratio, $7.4B free cash flow, and 2.49% dividend yield. Intuitive Surgical commands a premium 39x P/E multiple but delivers 21% revenue growth, zero debt, and dominance in robotic-assisted surgery. Both companies project ~13% sales growth for 2026, but Abbott's lower valuation and new Cologuard cancer screening acquisition make it the better buy for long-term value investors.

10/12/2026, 2:40 PM • The Motley Fool

4 Healthcare Stocks Worth Owning for the Next Decade

The article recommends four healthcare stocks across two key niches: GLP-1 weight-loss drugs (Eli Lilly and Novo Nordisk) and surgical robotics (Intuitive Surgical and Medtronic). Eli Lilly leads in GLP-1 but faces patent expiration risks, while Novo Nordisk is a turnaround story with attractive valuation. Intuitive Surgical dominates surgical robotics with strong recurring revenue, while Medtronic offers a diversified play with dividend appeal as it launches its Hugo surgical robot.

10/12/2026, 11:15 AM • The Motley Fool

Peers

Statistics

More
Day Range
$102.12
$103.84
$102.32
1-Year Range
$73.75
$105.35
$102.32
Latest Close$102.32
Change
-$0.56 (-0.55%)
Volume5,347,339
Market Cap$130.9B
Shares Outstanding1.3B
P/E (TTM)25.19
Diluted EPS (TTM)$4.06
Enterprise Value$157.3B

Information as of 11/17/2026

Company Profile

$130.9B
Market Cap
$5.2B
Net Income
Sector: Healthcare
Industry: Medical Devices
Building Two, Galway, Ireland, H91 4K49
353 1 438 1700

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys

Key Executives

  • Thierry Pieton
  • Geoffrey Straub Martha
  • Michelle Quinn
  • Michael Marinaro
  • Sally Saba

Current Ownership Distribution

  • Institutions21.4B (82.42%)
  • Mutual Funds4.5B (17.55%)
  • Insiders7.5M (0.03%)
  • Other0 (0.00%)